The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 15 - 2024 |
doi: 10.3389/fmicb.2024.1448710
This article is part of the Research Topic Diagnosis and Treatment Strategies of Tick-borne Diseases View all 3 articles
Clinical Factors Associated with Invasive Pulmonary Aspergillosis in Patients with Severe Fever with Thrombocytopenia Syndrome: Analysis of A 6-year Clinical Experience
Provisionally accepted- 1 Department of infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
- 2 Department of Medical Biosciences, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa
- 3 Department of Infectious Diseases, Bogomolets National Medical University, Kyiv, Ukraine
- 4 Research Institute of Virology, Ministry of the Health of Uzbekistan, Republic of Uzbekistan, Tashkent, Uzbekistan
- 5 Hai Phong University of Medicine and Pharmacy, Haiphong, Vietnam
Background: Invasive pulmonary aspergillosis (IPA) typically occurs in immunocompromised individuals. Severe fever with thrombocytopenia syndrome (SFTS) patients are typically characterized with fever, thrombocytopenia, and leukopenia. These patients typically present with dysregulation of cellular and humoral immunity, which may predispose them to IPA. Our study aimed to identify risk factors for SFTS-associated IPA and evaluate its associated prognostic impact. Methods: We conducted a cohort study between January 2017 and December 2022 in a tertiary hospital in Wuhan City, China. SFTS patients were divided into a SAPA group and a non-SAPA group according to whether they were coinfected with aspergillosis or not. The independent risk factors for SAPA group were determined by multivariate logistic regression. ROC analysis was used to assess the statistical value of parameters to predict SAPA patients. The survival analysis was carried out using the Kaplan-Meier (KM) method.Results: Of the 269 hospitalized SFTS patients enrolled in the study, 118 (43.87%) cases were diagnosed with SAPA with an average age of 65.71±9.7 years. Multivariate logistic regression analysis revealed that age, neurological complications, serum severe fever with thrombocytopenia syndrome virus (SFTSV) RNA loads, the white blood cell count (WBC), platelet count (PLT), albumin (ALB) and globulin (GLB) concentrations, cardiac Troponin I (c-TNI) as complementary risk factors for the development of IPA in SFTS patients. The risk score is calculated as 5 times Age, plus 6 times neurological complications, plus 10 times RNA (log), plus 5 times WBC, minus 5 times PLT, minus 5 times ALB, plus 5 times GLB, plus 6 times cTNI. ROC curve analysis showed that the area under the ROC curve (AUC) represented a risk score of 0.837 (95% CI: 0.789-0.885, p < 0.001) for predicting IPA in SFTS patients. The average length of hospitalization in the SAPA group was more prolonged than non-SAPA. The mortality rates of SAPA and non-SAPA groups are significantly different, 25.42% (SAPA) and 3.97% (non-SAPA), respectively (p < 0.05).SFTS patients with IPA have high morbidity and mortality. Early monitoring of neurological complications, SFTSV RNA loads, WBC, PLT, ALB, GLB, and c-TNI in SFTS patients may be useful in predicting the occurrence of IPA.
Keywords: Invasive Pulmonary Aspergillosis, Severe fever with thrombocytopenia syndrome, risk score, prognosis, Clinical experience
Received: 13 Jun 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Wang, Luo, Fisher, Pronyuk, Musabaev, Nguyen, Ye and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Erkin Musabaev, Research Institute of Virology, Ministry of the Health of Uzbekistan, Republic of Uzbekistan, Tashkent, 100194, Uzbekistan
Thi T. Nguyen, Hai Phong University of Medicine and Pharmacy, Haiphong, 10000, Vietnam
Pian Ye, Department of infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei Province, China
Lei Zhao, Department of infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.